Q-omics provides the consensus-scored RPSAP50 profile across patient tissues and cancer cell-line models. RPSAP50 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPSAP50 is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, RPSAP50 RNA expression shows 6,232 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, KIRP, and BRCA as cancer lineages where RPSAP50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP50 survival associations across molecular data types. RPSAP50 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP50 RNA expression–survival associations across cancer types. High RPSAP50 expression shows unfavorable associations in ACC, LGG, UCEC and STAD, but favorable associations in UVM and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for RPSAP50 RNA expression.
This table summarizes RPSAP50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP50 shows lower tumor expression in KIRP and KIRC. The KIRP box plot shows higher RPSAP50 RNA expression in normal versus tumor tissue (log2 FC = −0.049, t-test p = .015).
This table shows molecular features associated with RPSAP50 in patient tissues and cancer cell lines. In patient samples, RPSAP50 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
